Review demonstrates integration of traditional Chinese medicine and Western therapies for childhood asthma, suggesting improvements in outcomes and strategies.
Pediatric bronchial asthma is a heterogeneous disorder characterized by chronic airway inflammation, bronchial hyperresponsiveness, airflow limitation, and airway remodeling. Its cardinal manifestations include recurrent wheezing, coughing, dyspnea, and chest tightness, typically exacerbating nocturnally. While most pediatric patients achieve adequate disease control through standardized clinical management, untreated cases may persist into adulthood, leading to progressive pulmonary function decline and potential mortality. Beyond conventional pharmacotherapies-including bronchodilators, corticosteroids, immunosuppressants, and antihistamines-integrating traditional Chinese medicine (TCM) significantly reduces attack frequency, alleviates clinical symptoms, improves lung function, and enhances therapeutic efficacy. This review synthesizes recent advances in TCM etiology, pathogenesis, and syndrome-differentiation-based treatment for pediatric asthma during remission, alongside contemporary Western medical perspectives on epidemiology, diagnostic criteria, pathogenic mechanisms, and pharmacologic interventions. Our objective is to provide a theoretical foundation and clinical guidance for optimizing therapeutic strategies and improving long-term prognoses.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: